White SH, Brisson CD, Andrew RD. Examining protection from anoxic depolarization by the drugs dibucaine and carbetapentane using whole cell recording from CA1 neurons. As an immediate consequence of stroke onset, failure of the Na ϩ -K ϩ -ATPase pump evokes a propagating anoxic depolarization (AD) across gray matter. Acute neuronal swelling and dendritic beading arise within seconds in the future ischemic core, imaged as changes in light transmittance (⌬LT). AD is itself not a target for drug-based reduction of stroke injury because it is generated in the 1st min of stroke onset. Peri-infarct depolarizations (PIDs) are milder AD-like events that recur during the hours following AD and contribute to infarct expansion. Inhibiting PIDs with drugs could limit expansion. Two types of drugs, "caines" and 1receptor ligands, have been found to inhibit AD onset (and may also oppose PID initiation), yet their underlying actions have not been examined. Imaging ⌬LT in the CA1 region simultaneously with whole cell current-clamp recording from CA1 pyramidal neurons reveal that the elevated LT front and onset of the AD are coincident. Either dibucaine or carbetapentane pretreatment significantly delays AD onset without affecting resting membrane potential or neuronal input resistance. Dibucaine decreases excitability by raising spike threshold and decreasing action potential (AP) frequency, whereas carbetapentane eliminates the fast afterhyperpolarization while accentuating the slow afterhyperpolarization to reduce AP frequency. Orthodromic and antidromic APs are eliminated by dibucaine within 15 min but not by carbetapentane. Thus both drugs reduce cortical excitability at the level of the single pyramidal neuron but through strikingly different mechanisms. In vivo, both drugs would likely inhibit recurring PIDs in the expanding penumbra and so potentially could reduce developing neuronal damage over many hours poststroke when PIDs occur.
stroke; pyramidal; neuroprotection CORTICAL NEURONS UNDERGO a propagating wave of depolarization within 1-2 min following focal stroke onset, leading to formation of an ischemic core over hours. The extent of this ischemic or "anoxic" depolarization (AD) represents the most reliable determinant of ensuing brain damage (Kaminogo et al. 1998) . As the earliest upstream event leading to necrosis in the core, AD blockade is not considered a clinical target for improving stroke outcome because AD is over long before the patient reaches the endoplasmic reticulum (ER) and treatment can commence. However, in the hours following stroke onset, recurrent peri-infarct depolarizations (PIDs) spread from the edge of the ischemic core out into the penumbra (Nedergaard and Astrup 1986; Nedergaard and Hansen 1993) . Here, ATP levels fall ϳ50% compared with 75-90% in the core (Folber-grova et al. 1992) , so these events are AD-like but are able to repolarize. Their recurrence further depletes energy reserves of penumbral neurons over many hours and likely promotes dysfunction. PIDs increase both growth rate (Hartings et al. 2003) and volume of the core in rodent models (Back et al. 1996; Busch et al. 1996; Takano et al. 1996) . They can be imaged coursing along the surface of mouse neocortex following focal stroke (Farkas et al. 2008) . Clinically, PIDs are recorded from the cortical surface of patients in the hours and days following head trauma (Fabricius et al. 2006) or stroke (Dohmen et al. 2008 ). Thus a surprisingly prolonged "window of opportunity" is available for suppressing these recurring events.
During AD, extracellular K ϩ suddenly climbs to 50 -60 mM, whereas extracellular Na ϩ (from 130 to ϳ50 mM) and Ca 2ϩ (from ϳ2 to 0.1 mM) decrease precipitously (Lipton 1999) . These ionic movements toward ionic equilibrium are initially through voltage-gated channels and possibly through pannexin-1 hemichannels (Thompson et al. 2006 ). Rupturing of neurons would also support such change over the longer term. Reducing extracellular Na ϩ from ϳ145 to 28 mM does not significantly alter AD onset , although AD amplitude is reduced in low extracellular Na ϩ . Glutamate receptor activation is not required for the generation or propagation of cortical AD in adult rodent slices (Anderson et al. 2005; Jarvis et al. 2001; Muller and Somjen 2000; Tanaka et al. 1997 ) and in vivo (Hernandez-Caceres et al. 1987; Lipton 1999; Murphy et al. 2008; Nellgard and Wieloch 1992) . There is no evidence that any transmitter agonist or antagonist affects AD onset, probably because synapses fail before AD onset. AD is also not stopped by blocking of synaptic transmission with low calcium (Jarvis et al. 2001; Obeidat et al. 2000; Obrenovitch et al. 2000) or with K ϩ or Ca 2ϩ channel blockers ). On the other hand, numerous studies have found that the "caine" family of Na ϩ channel blockers significantly delay AD onset (Taylor et al. 1999; Urenjak and Obrenovitch 1996; Weber and Taylor 1994) . This is also true for some -receptor (R) ligands (Anderson et al. 2005) . Like the caines, certain R ligands have been proposed to be neuroprotective in models of stroke and Alzheimer's disease (Maurice and Su 2009 ). Neither type of drug has been examined with intracellular recording to observe drug effects at the level of the cortical neuron.
A reasonable assumption is that a drug blocking or delaying AD onset will also inhibit PID onset in vivo. However, PIDs are difficult to distinguish from spreading depression (SD) in vivo. A PID that propagates into uncompromised tissue is essentially an SD event. Although not measured to date, small amounts of both drugs likely cross the blood-brain barrier because dibucaine is neurotoxic at higher concentrations in patients, whereas carbetapentane (CP) is quite lipophilic (log P value of 4.2). Here, we examine how dibucaine, a potent Na ϩ channel blocker (APPENDIX) and AD inhibitor, works at the level of the single pyramidal neuron to reduce susceptibility to AD (and probably to PIDs as well). We compare the effects of dibucaine with CP (a R ligand that also delays AD onset) to try to identify a common mechanism of AD inhibition. (For more information on both compounds, see APPENDIX.) 
METHODS

Hippocampal Slice Preparation
A protocol including these studies was approved by the Queen's University Animal Care Committee. Male Sprague-Dawley rats, 21-28 days old (Charles River, Saint-Constant, Québec, Canada), were cared for in accordance with the Canadian Council on Animal Care. They were housed in a controlled environment (22 Ϯ 1°C, 12:12-h light-dark cycle) with Purina rat chow and water supplied ad libitum. A rat was placed in a rodent restrainer and guillotined. The brain was excised within 1 min and placed in ice-cold oxygenated (95% O 2 -5% CO 2 ) high-sucrose artificial cerebrospinal fluid (aCSF). Hippocampal slices ( Fig. 1A) were cut in the coronal plane (400 m) using a vibrating blade microtome (Leica VT1000 S; Wetzlar, Germany). Slices were transferred to a net submerged in a beaker of regular aCSF gassed with O 2 -CO 2 at 22°C and slowly warmed to 31°C over 1 h for electrophysiological recording and imaging. Experiments involving AD were performed at 35°C.
Experimental Solutions
Control aCSF contained (in mM): 120 NaCl, 3.3 KCl, 26 NaHCO 3 , 1.3 MgSO 4 , 1.2 NaH 2 PO 4 , 11 D-glucose, and 1.8 CaCl 2 (pH 7.3-7.4, 295 mosmol/kgH 2 O). High-sucrose aCSF included 240 mM sucrose instead of NaCl. Before electrophysiological recording, individual slices were transferred to a submersion chamber (RC-26; Warner Instruments, Hamden, CT) and held down with a slice anchor (SHD-26H; Warner Instruments). Constant aCSF flow of 1-2 ml/min was maintained throughout the experiments. Ischemia was simulated by either oxygen/glucose deprivation (OGD) or addition of the Na ϩ -K ϩ -ATPase inhibitor ouabain (100 M). Both evoked similar AD with respect to changes in light transmittance (⌬LT) and electrophysiology (Jarvis et al. 2001) . For OGD, aCSF glucose was replaced with equimolar NaCl, and the 95% O 2 -5% CO 2 mixture gassing the aCSF was replaced with 95% N 2 -5% CO 2 . Dibucaine hydrochloride or the high-affinity R1 ligand CP (citrate salt) from Sigma-Aldrich were dissolved in double-distilled water and applied by bath.
Single-Cell Electrophysiology
The micropipette solution contained (in mM): 130 K ϩ -gluconate, 10 KCl, 1.1 MgCl 2 , 5 EGTA, 10 HEPES, 2 Na ϩ -ATP, and 0.1 CaCl 2 . The pH was adjusted to 7.3 with KOH, and osmolality was 270 mosmol/kgH 2 O. In one group of experiments, 10 or 100 M dibucaine was added to the micropipette solution, replacing equimolar K ϩ -gluconate. CA1 pyramidal cells or granule cell neurons ( Fig. 1A) were "blind"-patched with micropipettes pulled from borosilicate glass capillaries (1.2-mm inside diameter) to a resistance of 3-6 M⍀. All recordings were performed in whole cell current-clamp using "bridge" mode of an Axoclamp 2A amplifier, sampled using a Digidata 1322A A/D converter (Molecular Devices, Sunnyvale, CA). An external Bessel filter (LPF 202a; Molecular Devices) provided low-pass filtering at 10 Hz. Pipette junction potentials were corrected just before achieving whole cell mode. Series resistance was compensated by 70%. Seal resistance was estimated at Ͼ1 G⍀. Bath application of a drug was initiated only after a stable membrane potential was obtained and Ͻ5 min had passed to allow for dialyzing the pipette solution into the cell. Neuronal recordings were acquired before and following 30 min of drug administration by bath at 31°C. Initial control values of several electrophysiological parameters were pooled and compared with the post-30-min values. Data were analyzed offline with Clampex software (version 10.1). Then, temperature was slowly increased to 35°C over 10 min for a total of 40 min of drug pretreatment before inducing simulated ischemia with OGD. Several properties of the induced AD were measured (Fig. 1B) .
The current pulse injection protocol was nine sequential 1-s current steps of 100 pA ranging between Ϫ500 and 300 pA and occurring every 6.5 s. Trains of action potentials (APs) were elicited at depolarizing current levels, and estimates of whole cell input resistance were obtained from the slope of the current-voltage relationship (I-V) curve at negative current pulse levels using Clampfit software.
Orthodromic responses by CA1 neurons were evoked by stimulating Schaffer collaterals of CA3 axons in stratum radiatum (Fig. 1A) using a concentric bipolar electrode (Rhodes Electronics, Woodland Hills, CA) with a shaft diameter of 0.25 mm. An antidromic response Fig. 1 . A: "blind" patch-clamp recording from the CA1 hippocampal neurons were made in current-clamp mode. Orthodromic (ortho.) action potentials (APs) of CA1 neurons were activated by stimulating (stim.) the stratum radiatum (RAD) near the CA3 region, and antidromic (anti.) activation involved stimulating the alveus. Single-cell recording in the granule cell layer (GC) was in the upper blade. Sch. collat., Schaffer collaterals; PYR, pyramidal neurons; OR, stratum orions; RAD, stratum radiatum; LM, lacunosum moleculare. B: individual components of the anoxic depolarization (AD) trace recorded under current-clamp in the single cell. AD initiation (1) is the point where the initial slow depolarization transitions to a more rapid depolarization (in minutes and seconds). The peak potential (2) of the AD is the point where the slope of the fast AD transitions to the slope of the late depolarization (in millivolts). The fast AD amplitude (3) was measured between AD initiation and the peak potential (in millivolts). The duration of the late depolarization (4) was measured between the peak potential and the maximal depolarization (in seconds). I Naϩ , Na ϩ currents; OGD, oxygen-glucose deprivation. was elicited by stimulating the alveus adjacent to the recorded CA1 neuron. Stimulation (0.5 ms in duration, 0.1 Hz) was at the minimal strength to evoke a single AP, which was monitored until failure or until the 30-min drug treatment elapsed. After orthodromic failure, excitatory postsynaptic potential (EPSP) amplitude continued to be monitored at the same stimulus strength and frequency.
Imaging ⌬LT ⌬LT of the slice were monitored in real-time during OGD. Cell swelling was imaged as an increase in LT during AD initiation/ propagation in cortical brain slices. Dendritic damage was imaged as decreased LT in the wake of the AD front that followed the LT increase (Obeidat and Andrew 1998) . This LT reduction results from light scattering caused by dendritic beads forming within minutes of AD onset in brain slices (Andrew et al. 2002; Jarvis et al. 1999; Polischuk et al. 1998 ). This coincides with comparable beading during AD in the intact mouse neocortex detected as a reduction in light reflectance (Murphy et al. 2008) . The slice was illuminated using a broadband, voltage-regulated halogen light source ( Fig. 2A ) on an upright light microscope. The light traversed a band-pass filter that transmitted red and near-infrared light (690 -1,000 nm). Video frames were acquired using a 12-bit digital camera (Hamamatsu C4742-95) set to an exposure time of 0.05 s. Images were acquired at 32 frames/s and averaged using Imaging Workbench (IW6) software (INDEC BioSystems, Santa Clara, CA). To synchronize imaging with electrophysiology, Clampex software triggered the IW6 image acquisition. The first averaged image in a series served as a control (T 0 ), which was subtracted from each subsequent experimental image of that series (T). The resulting series of subtracted images revealed changes in LT over time [using the formula ⌬T/T 0 ϭ (T Ϫ T 0 )/T], which was displayed using a pseudocolor intensity scale ( Fig. 2A ). Zones of interest were selected to quantify and display graphically the ⌬LT data offline. Graphing and statistical analyses of data were carried out using SigmaPlot for Windows (Jandel Scientific) or Microsoft Excel. Images were imported, and figures were prepared using CorelDRAW Graphics.
Statistical Analysis
Neurons were analyzed if they displayed stable resting membrane potentials of at least Ϫ55 mV and if the series resistance and capacitive currents could be sufficiently compensated. Recordings were terminated if access resistance increased to where it could not be compensated using the bridge balance. Statistical significance was determined by unpaired t-tests, and all data are presented as means Ϯ standard deviation. Control data were pooled before drug application and compared with a 30-min pretreatment of each concentration and drug type. The significance criterion was set at P Ͻ 0.05.
RESULTS
Simultaneous Current-Clamping and ⌬LT Imaging During OGD
Within 6 min of OGD, a front of elevated LT coursed through the gray matter of the CA1 region ( Fig. 2A ), propagating at a rate of 2-4 mm/min. AD onset time in the CA1 region was measured as the time point when the LT front Fig. 2 . A: the equipment consisted of a broadband halogen light source focused on the slice where light was transmitted, absorbed, or reflected. Transmitted light was collected by the digital camera and processed by the camera controller (charge-coupled device, CCD). Increases in light transmittance (LT) were pseudocolored blue-green-yellow, and decreases in LT were pseudocolored magenta. ⌬T%, change in light transmittance. B: imaging of LT during single-cell current-clamp in CA1 neurons. Pseudocolored images demonstrate LT changes as a result of OGD. The AD front was observed as a wave of increased LT propagating along the length of the CA1 region. Following in the wake of the AD front was as a reduced LT within the dendritic regions (stratum oriens and stratum radiatum), the result of light scattering by beaded, injured dendrites (Andrew et al. 2007; Obeidat and Andrew 1998) . Meanwhile, the stratum pyramidale continued to show increases in LT denoting pyramidal soma swelling even after artificial cerebrospinal fluid (aCSF) reintroduction within seconds after the passing AD front. Time is shown as minutes: seconds. C: a current-clamp recording in CA1 showed that the fast AD was concurrent with the front of elevated LT passing the recording electrode. INHIBITING ANOXIC DEPOLARIZATION passed by the recording electrode (Fig. 2 , B and C; 4:37 min), an average of 5.3 Ϯ 1.3 min after switching to OGD (n ϭ 41 slices). Under whole cell current-clamp, the recorded AD waveform was subdivided into 3 components: a small but prolonged early depolarization, an ensuing rapid depolarization (the fast AD) coincident with the LT front, and a later slow depolarization that approached 0 mV ( Fig. 1B) . CA1 cells consistently underwent fast AD (mean amplitude 28.8 Ϯ 6.2 mV), coinciding with the LT front passing the micropipette (n ϭ 13; Table 1 ) with a slope of 2.7 Ϯ 1.5 mV/s and a peak potential of Ϫ9.4 Ϯ 4.6 mV. The slower, late depolarization (also called the persistent depolarization) had a slope of 0.28 Ϯ 0.16 mV/s and took an average of 46.4 Ϯ 31.3 s before reaching 0 mV. Six additional recordings were obtained without ATP in the pipette (to eliminate the possibility of this additional energy source interfering with the AD waveform). The absence of ATP in the pipette had no discernible effect on AD (data not shown).
Following AD, membrane potential remained near 0 mV while the slice evolved optical signs of damage (Fig. 2B , bottom right). There was no evidence of repolarization as monitored for up to 30 min post-OGD. There was also a continued decrease in LT within CA1 dendritic regions over the minutes following AD propagation with no sign of recovery after return to control aCSF. The reduction in LT in these regions is partly the result of dendritic beading that scatters light despite maintained slice swelling (see DISCUSSION) . Once AD propagated, the LT decrease was inevitable, although some neurons could return to near baseline membrane potential if OGD was immediately terminated on AD initiation (data not shown).
Bath Pretreatment with Dibucaine or CP
An important initial component of AD is a massive influx of Na ϩ into neurons, so various attempts to inhibit AD have involved the use of sodium channel blockers. Dibucaine has proven to be the most effective caine tested in our laboratory based on imaging ⌬LT (Douglas et al. 2011) . As demonstrated with other caines (Creveling et al. 1983 ), bath-applied dibucaine is thought to enter neurons slowly through briefly opened Na ϩ channels and then bind to the channel on the intracellular side to block the pore. In the current study, hippocampal slices preexposed to 40 min of 10 M dibucaine displayed significantly delayed AD onset from 5.3 Ϯ 1.3 to 9.3 Ϯ 1.9 min (P Ͻ 0.001) in nine slices tested (Fig. 3 , A and C). Pretreatment with 1 M dibucaine caused no delay in this CA1 study ( Fig. 3C ) but was significantly effective on AD onset in neocortical slices (Douglas et al. 2011 ).
CP, a 1R ligand, was previously tested in our laboratory and found to delay the onset of AD. We reaffirmed that pretreatment of slices for 40 min with 10 or 30 M CP significantly delayed AD. Onset times were 7.2 Ϯ 1.8 min (n ϭ 13; P Ͻ 0.05) and 10.4 Ϯ 1.6 min (n ϭ 6; P Ͻ 0.001), respectively, from a control value of 5.3 Ϯ 1.3 min ( Fig. 3C ). Increasing CP pretreatment to 100 M for 40 min eliminated the evoked CA1 population spike (data not shown), so a 20-min exposure was used. AD was significantly delayed by 100 M CP (8.5 Ϯ 0.8 min, n ϭ 4) compared with control (5.3 Ϯ 1.3 min, n ϭ 25) but less so than 30 M CP (10:24 Ϯ 1:34 min, n ϭ 6) because of the reduced pretreatment time (Fig. 3C ).
Dibucaine Introduction Intraneuronally
Single CA1 pyramidal cells. The primary pharmacological effects of dibucaine have been attributed to its binding within the voltage-gated sodium channel, but it also has poorly defined effects on the membrane itself. As an alternative to bath exposure, we directly introduced 10 or 100 M dibucaine through the recording pipette. This tested whether the AD recorded in the single neuron exposed to the drug could be altered as the LT front passed through neighboring neurons and glia not exposed to the drug. Dibucaine acting within the recorded cell alone could not slow or stop the fast AD as measured either electrophysiologically or as the LT wave front. This is not surprising because AD is a population event. However, either concentration of dibucaine clearly slowed depolarization of the recorded cell itself, particularly during the late AD (Fig. 4 , A-C). Ten micromolar dibucaine increased the late AD duration by Ͼ50% to 73.2 Ϯ 37.2 s (P Ͻ 0.05; n ϭ 11), whereas 100 M dibucaine increased it by Ͼ250% to 124.5 Ϯ 50.9 s (P Ͻ 0.001; n ϭ 14; Fig. 4 , B and C, and Table  1 ). Dibucaine at 100 M also reduced the mean amplitude, peak potential, and slope of the fast AD as well as the slope of the late AD (Table 1) . However, inevitably, the neuron completely depolarized.
Single-granule cells. AD propagation is also imaged in the dentate gyrus (data not shown). To examine whether the intracellular effects of dibucaine on AD were specific to CA1 pyramidal cells, granule cells of the dentate gyrus were recorded without ( Fig. 5A ) and with ( Fig. 5B ) 10 M dibucaine in the pipette. This concentration reduced the fast AD amplitude from 23.3 Ϯ 8.2 mV in 10 untreated granule cells to 15.8 Ϯ 5.3 mV (P Ͻ 0.01; n ϭ 13; Table 2 ). Moreover, it reduced the peak potential of the fast AD from Ϫ11.4 Ϯ 6.0 mV in untreated granule cells to Ϫ23.3 Ϯ 6.3 mV (P Ͻ 0.01). Importantly, the latency to reach 0 mV following AD increased to 132.7 Ϯ 63.7 s compared with 44.2 Ϯ 27.1 s (P Ͻ 0.001) in Values are means Ϯ SD. *P Ͻ 0.05; †P Ͻ 0.01. Dib, dibucaine; fast AD ampl, amplitude of fast component of anoxic depolarization (AD); peak potential, peak amplitude of the depolarization; slope of fast AD, slope of the fast component of AD; slope of slow depol, slope of slow component of depolarization; late AD duration, duration of the late or persistent depolarization. untreated granule cells (Table 2 ). Thus 10 M dibucaine pretreatment slowed AD progression within individual granule cells in a manner similar to CA1 neurons. As expected, simply attempting to block AD in the single neuron did not affect AD within the population. The remnant of the fast AD recorded in these neurons (and CA1 cells) may actually be driven by the rise in extracellular K ϩ concentration from AD generated in neighboring neurons.
Dibucaine and Ouabain-Induced AD
Adding 100 M ouabain to aCSF initiated an event similar to OGD-induced AD (Fig. 6A ). Ouabain directly inhibits the Na ϩ -K ϩ -ATPase by binding to the pump on the extracellular side of the plasma membrane. Latency to AD onset induced by ouabain (6.3 Ϯ 0.1 min, n ϭ 17) was not statistically different from slices exposed to OGD (5.3 Ϯ 1.3 min, n ϭ 11). Ouabain induced a slightly steeper fast AD (slope of 3.9 Ϯ 1.3 mV/s) compared with OGD (2.7 Ϯ 1.5 mV/s). As well, ouabain increased the peak potential (Ϫ4.0 Ϯ 1.8 mV) compared with OGD (Ϫ9.4 Ϯ 4.6 mV; P Ͻ 0.05; Table 3 , Fig. 6A ). Therefore, ouabain-induced AD was qualitatively similar to that induced by OGD but progressed slightly faster and was marginally more depolarizing.
Ten micromolar dibucaine pretreatment for 40 min prevented AD in all six slices exposed to 10 min of 100 M ouabain. This was more dramatic than the simple delay in onset induced by OGD. However, with ouabain, the membrane potential did slowly depolarize from a resting level of around Ϫ65 mV to a mean level of Ϫ26.0 Ϯ 5.50 mV by 10 min of ouabain (Table 3 , Fig. 6B ). So, compared with Fig. 3 . Bath-applied drug pretreatment for 40 min prolongs the latency to AD onset evoked by 10-min OGD and recorded in CA1 neurons under currentclamp. A and B: representative trace of AD delay induced by 10 M dibucaine (Dib) and 10 M carbetapentane (CP). Note that unlike Dib, CP did not block APs (arrow), consistent with it not raising spike threshold (although amplitude was reduced). C: mean AD onset times in drug-treated slices, measured as the increased LT front passed the recording electrode. Significant differences compared with controls were induced by 10 M Dib as well as 10 -100 M CP. complete depolarization induced by ouabain alone (Fig. 6A) , 10 M dibucaine inhibited the fast AD such that the CA1 neuron only partially depolarized and then remained at about Ϫ40 mV for the duration of the recording, essentially blocking a full-blown AD.
Drug Effects on CA1 Intrinsic and Synaptic Properties
Bath-applied dibucaine effects. To help characterize how dibucaine may delay AD onset and progression, single CA1 neurons were whole cell-patched under current-clamp mode to measure changes in their intrinsic and synaptic electrophysiological properties. An AP train evoked by a depolarizing pulse lasting 1 s revealed changes in AP threshold and waveform depending on the drug and its concentration (Fig. 7, A and B) .
Neither resting membrane potential nor whole cell input resistance were altered after 30 min of bath pretreatment with either 1 or 10 M dibucaine (Table 4 ). During depolarizing current injection, 1 M dibucaine did not alter the fast afterhyperpolarization (fAHP), AP threshold, AP frequency, or AP duration. A surprisingly small reduction in AP amplitude (P Ͻ 0.05) was noted, however, in nine CA1 cells examined. Increasing dibucaine concentration to 10 M enhanced the fAHP amplitude (measured relative to the AP threshold) from Ϫ3.4 Ϯ 1.9 mV (n ϭ 45, control aCSF) to Ϫ10.8 Ϯ 3.7 mV (n ϭ 20, 10 M dibucaine; P Ͻ 0.001; Fig. 8A , Table 4 ). The slow afterhyperpolarization (sAHP) of the last AP in the train increased from Ϫ5.8 Ϯ 1.8 to Ϫ15.8 Ϯ 5.0 mV (P Ͻ 0.01; Fig.  8B ). Ten micromolar dibucaine pretreatment also increased AP threshold, shifting it from Ϫ47.5 Ϯ 4.4 mV (n ϭ 45, control aCSF) to Ϫ37.7 Ϯ 4.5 mV (n ϭ 20; P Ͻ 0.001; Figs. 7B and 9A, Table 4 ). Corresponding reductions in AP frequency at all three current injection levels (Fig. 9B, Table 4 ) were likely caused by the increase in AP threshold as well as the increase in both the fast and slow AHP amplitudes.
AP duration measured at half-AP amplitude was unchanged by both 1-and 10 M dibucaine after the first AP in the train (Table 4 ). However, after the last AP in the train (measured at the highest current injection level), AP duration (measured at half-AP amplitude) increased from 1.2 Ϯ 0.2 to 2.0 Ϯ 1.7 ms (n ϭ 9; P Ͻ 0.01; Table 5 ). This was perhaps facilitated by Na ϩ channel inactivation by the drug, as dibucaine is known to induce a use-dependent block by binding inactivated Na ϩ channels.
To investigate drug actions further, single APs were synaptically evoked in CA1 neurons by orthodromic stimulation of the CA3 Schaffer collaterals. Antidromic activation was also evoked by stimulating the alveus region. One micromolar dibucaine was not tested further as it was ineffective at this concentration. Orthodromic APs were lost an average of 7.4 Ϯ 2.4 min (n ϭ 8) after 10 M dibucaine exposure measured at 0.5 V above the initial voltage strength required to evoke a typical response (P Ͻ 0.01; Fig. 10A, left) . AP threshold continued to increase over the following 5-10 min until the evoked spike failed. Evoked EPSPs continually decreased in amplitude over the 30-min treatment, from a maximum of 14.8 Ϯ 5.0 mV at initial AP loss to 6.3 Ϯ 5.0 mV (P Ͻ 0.05; n ϭ 8). Antidromic spikes were more resistant to block, taking an average of 15.0 Ϯ 14.6 min to fail at the initial stimulus strength (P Ͻ 0.01; Fig. 10A, right) . It remained possible to evoke an antidromic AP by increasing the stimulus voltage (data not shown).
After 30 min of pretreatment with 10 M dibucaine, antidromic APs displayed slightly enhanced depolarizing afterpotentials (DAP) at 3 and 5 ms (Fig. 10, B and C) . However, as recorded in 24 CA1 neurons, this enhancement was not statistically significant compared with drug-free aCSF.
Bath-applied CP effects. CP also reduced excitability in CA1 pyramidal neurons, although in markedly different ways from dibucaine. AP frequency was significantly reduced in 10 and 30 M CP (P Ͻ 0.05; Table 4 ) and in 100 M CP (P Ͻ 0.001) as shown in Fig. 7 , A and C. Unlike dibucaine, this slower AP discharge was not the result of an increase in AP threshold at 10 or 100 M CP (Fig. 8A ). AP duration, as measured at half-AP amplitude, did increase in both 30 and 100 M CP to 1.4 Ϯ 0.9 and 2.0 Ϯ 2.6 ms, respectively (n ϭ 5) from a control value of 1.0 Ϯ 0.1 ms (P Ͻ 0.01) as shown in Table 4 . The threshold of the last AP in the train increased following 30-min pretreatment with 30 M CP from Ϫ41.2 Ϯ 4.0 mV to Ϫ34.3 Ϯ 4.3 mV or with 10 M CP pretreatment to Ϫ31.1 Ϯ 4.0 (Fig. 9A , Table 5 ). The fAHP was notably eliminated in the first AP of the train in all three concentrations, apparently facilitating spike train discharge (Table 4) . Conversely, by the last AP in the train, the sAHP amplitude increased to Ϫ11.2 Ϯ 2.9 mV (P Ͻ 0.01) in 10 M CP and Ϫ10.6 Ϯ 2.3 mV in 30 M CP (n ϭ 11; P Ͻ 0.01) from a control value of Ϫ5.8 Ϯ 1.8 mV (n ϭ 25; Fig. 8B , Table 5 ).
The last AP in the train was not measured with 100 M CP because only a single AP or AP doublet could be evoked.
When single APs were evoked by either antidromic or orthodromic stimulation, DAP amplitude (measured at 3 and 5 ms) was enhanced following pretreatment with 30 M CP to 18.7 Ϯ 5.3 mV and 15.5 Ϯ 2.8 mV (P Ͻ 0.01), respectively, from control values of 11.3 Ϯ 2.5 and 10.9 Ϯ 2.5 mV (Fig. 10,  B and C) . One hundred micromolar CP enhanced the DAP to 31.9 Ϯ 7.7 and 21.8 Ϯ 3.9 mV as measured in six CA1 cells (P Ͻ 0.01; Fig. 10C ). At 100 M CP, orthodromic APs failed at ϳ30 min. Unlike dibucaine, APs could still be evoked at higher voltages, as tested in three CA1 cells (data not shown). Furthermore, antidromic stimulation (at baseline strength) could generate APs for the entire 30 min of CP exposure in five of six cells with 30 M CP and one of three cells with 100 M CP (data not shown). This suggests that the CP was altering spike-related currents more in the soma-dendritic region than in the axon.
Combined Bath-Applied Effects of Dibucaine and CP
Our observations that dibucaine and CP each reduced the excitability of CA1 neurons through different mechanisms prompted us to search for additive effects of both drugs on the excitability of single neurons. Following 30-min pretreatment with 1 M dibucaine and 10 M CP, the intrinsic electrophysiological properties of 14 CA1 cells (Table 4) were not significantly different from pretreatment with 10 M CP alone. The exception was the fAHP, which was preserved in 8 of 14 cells (Table 4 ). The inclusion of 3 M dibucaine with 30 M CP Values are means Ϯ SD. *P Ͻ 0.05; †P Ͻ 0.01. OGD, oxygen/glucose deprivation. Fig. 7 . AP discharge by CA1 neurons is attenuated by both Dib and CP but by different mechanisms. All recordings had resting potentials between Ϫ61 and Ϫ64 mV. A: an AP train in control aCSF during a 100-pA depolarizing current pulse lasting 1 s (initiated at the arrow). B: a 30-min pretreatment with 10 M Dib required a 200-pA injection to fire a maximum 2 APs. Dib reduced AP frequency by raising the AP threshold (Table 4) . C: a 30-min pretreatment with 100 M CP also reduced AP frequency but without a corresponding increase in threshold (Table 4 ). Rather, CP increased post-AP afterhyperpolarizations and slowed AP discharge rates. raised the AP threshold of the 1st AP in the train to Ϫ38.8 Ϯ 4.6 mV compared with Ϫ49.1 Ϯ 2.8 mV with 30 M alone (P Ͻ 0.01; Fig. 9A , Table 4 ). The increased AP threshold observed at these drug concentrations caused an expected reduction in AP frequency compared with 30 M CP alone (P Ͻ 0.001; Fig. 9B , Table 4 ). The effect of pretreatment with dibucaine and CP on intrinsic CA1 properties therefore appeared to be additive.
DISCUSSION
AD is imaged as a focally initiating, and then propagating, increase in LT (Anderson et al. 2005; Jarvis et al. 2001; Obeidat and Andrew 1998; Somjen 2001) . Extracellular recording simultaneously with ⌬LT imaging reveals a wave front of elevated LT corresponding with a sudden negative shift in extracellular direct current (DC) potential that represents a depolarization by the neuronal population (Jarvis et al. 2001; Muller and Somjen 1999) . We recorded AD in single pyramidal neurons while simultaneously imaging ⌬LT within the coronal cerebral slice to study AD initiation and potential recovery. Combining these techniques also helps clarify previous experiments concerning AD delay induced by either dibucaine or CP. Either drug that delayed AD at lower concentrations also preserved synaptic function based on evoked population responses, suggesting that AD could be inhibited without undermining normal cortical function (Douglas et al. 2011) . Here, we looked at the level of the single neuron to determine how these drugs may be protective by delaying AD onset and, by extension, inhibiting recurring PIDs. Delaying AD or PID onset protects because gray matter spends less time postdepolarization exposed to OGD, which is when neurons become irreversibly damaged.
Drug Effects on AD Initiation
Bath pretreatment with dibucaine. Previous experiments in our laboratory showed that 1 M dibucaine pretreatment delayed AD and at the same time preserved evoked synaptic function in both cortical and hippocampal neurons (Anderson et al. 2005) . The present experiment did not detect a delay in AD with 1 M dibucaine, probably due to the shorter pretreatment time of 30 min. Ten micromolar dibucaine pretreatment, however, was found to delay AD in the present experiment significantly.
With 10 M dibucaine, the evoked CA1 field potential was reduced by 80% (Douglas et al. 2011) . Our current intracellular work revealed that both the orthodromic and antidromic APs were blocked and that evoked EPSP amplitude was significantly reduced during the 30-min pretreatment. It is likely that the inhibition of AD onset by dibucaine at 10 M results in part from suppression of AP firing by blocking both the sustained and the slow Na ϩ currents (I NaS ). OGD itself blocks the fast Na ϩ current, thereby dampening AP discharge and thus synaptic transmission. Additional intracellular parameters were measured to delineate better how reducing pyramidal cell excitability may delay AD, thus providing neuroprotection.
The best documented effect of dibucaine is its action on the local anesthetic binding site within voltage-gated Na ϩ channels (Kuroda et al. 2000; Ragsdale et al. 1994 ), although direct Fig. 8 . Enhancing AP afterhyperpolarization reduces firing. A: the CA1 fast afterhyperpolarization (fAHP) was measured relative to AP threshold (dashed line), the 1st AP of a train evoked by a 1-s depolarizing current pulse. The fAHP was measured relative to AP threshold (dashed line). The fAHP significantly increased in amplitude and duration following 10 M Dib treatments. In contrast, CP at 10 -100 M eliminated the fAHP, resulting in a pronounced depolarizing afterpotential (DAP). B: the slow afterhyperpolarization (sAHP) that followed the 1st AP of a train evoked by a 1-s depolarizing current pulse was also examined. Compared with control, both Dib and CP increased the sAHP amplitude and duration. A 30 M CP exposure inhibited the fAHP enough to reveal a DAP. Despite this, the prolonged sAHP enhancement helps account for the slowed firing displayed in Fig. 7 . Table 4 
. Drug effects on the intrinsic properties of CA1 neurons
Control (n ϭ 45) 3 M Dib (n ϭ 9) 10 M CP (n ϭ 12) 30 M CP (n ϭ 11) 100 M CP (n ϭ 5) measurements of the various Na ϩ currents reduced by dibucaine have not been carried out. Lidocaine is a similar (but less potent) caine that reduces the voltage-activated Na ϩ current in isolated pyramidal neurons (Kaneda et al. 1989) .
Intracellular introduction of dibucaine. Dibucaine slowed AD progression when introduced into the single pyramidal neuron or granule cell, even as surrounding neurons go through the standard, faster AD. The fact that dibucaine was able to reduce the fast AD amplitude while delaying the late depolarization indicates that the single neuron itself can dictate much of the intracellular AD waveform. However, a remnant of the fast AD was always recorded. Note that a fast AD is also recorded in astrocytes (data not shown), suggesting that the fast AD is partly generated by sudden efflux of K ϩ by the surrounding neurons synchronously undergoing AD. The current responsible for the fast AD involves Na ϩ , Cl Ϫ , and Ca 2ϩ influx and K ϩ efflux (Czeh et al. 1993) but is also driven passively by the sudden increase in K ϩ to ϳ50 mM. The late depolarization has been attributed to inward Na ϩ and Ca 2ϩ currents .
Bath pretreatment with CP. The mode of action on central nervous system (CNS) neurons of R ligands had not been examined in detail. Our study supports previous limited data showing no change in CA1 membrane potential, cell input resistance, or AP threshold during 50 min of exposure to 100 M dextromethorphan (Wong et al. 1988) or to the R ligand OPC-24439 (Ishihara et al. 1999) . Our CP pretreatment reduced CA1 excitability, but, unlike dibucaine, CP did not increase the AP threshold. It did increase the sAHP, which likely helped slow the firing rate. Rs have been localized to plasma membrane, mitochondrial membrane, and dendrites (Alonso et al. 2000) , and no staining has been observed on the axons of presynaptic neurons (Alonso et al. 2000) . So, AD delay by CP likely involves the CA1 soma-dendritic region. The unchanged antidromic AP evoked in our study confirms the lack of a R ligand effect at the level of the axon. R ligands have been shown to inhibit voltage-activated K ϩ current in tumor cells (Wilke et al. 1999 ) and in oocytes expressing voltage-gated K ϩ channels and R (Aydar et al. 2002) . Specific potassium channel effects observed in cardiac cells include decreased delayed outwardly rectifying potassium current, large-conductance (BK) current, and M-current (Zhang and Cuevas 2005) . Calcium-activated potassium channels such as BK, small conductances (SK), and intermediate conductance (IK) underlie the AHP in neurons. CP enhanced the sAHP in our study, which would also explain the spike frequency adaptation that we observed (Sah 1996) . The spike broadening by CP is also suggestive of BK channel block through its role in spike repolarization.
Some R ligands (including CP) are neuroprotective in cortical neurons (Hayashi et al. 2000; Katnik et al. 2006) , where the authors measured Ca 2ϩ increase under simulated ischemia. CP attenuated the increase in intracellular calcium caused by sodium azide (which blocks aerobic metabolism) and glucose deprivation in cultured cortical neurons. This was attributed to direct preservation of intracellular Ca 2ϩ homeostasis. The IC 50 value (13 M CP) required to attenuate Ca 2ϩ increases caused by simulated ischemia in cultured neurons corresponds to values obtained in our experiments showing AD delay in brain slices.
Dibucaine effects on ouabain-induced AD. Low concentrations of dibucaine have been shown to block AD during 10 min of ouabain exposure (Douglas et al. 2011) , but it was unclear whether the drug maintains neurons at a normal resting potential. Our current-clamp recordings with dibucaine show that there is a small but steady depolarization that would not be detected with extracellular DC recording. Thus the lack of a DC shift makes it appear that AD was fully blocked (Douglas et al. 2011 ) when in fact a slow depolarization was ongoing, which would reduce the evoked population spike. Ouabaininduced AD is more easily blocked with equivalent drug concentrations than OGD-induced AD (Anderson et al. 2005). Comparing the role of dibucaine in AD delay as a reduction in metabolic load seems to contradict its ability to delay AD induced by ouabain, which is independent of tissue ATP levels (Anderson et al. 2005) . It seems likely that dibucaine protects from ouabain and OGD in a similar fashion by inhibiting currents associated with the AD that open as a result of Na ϩ -K ϩ pump failure.
Actions of Dibucaine and CP
Our findings show a reduced neuronal excitability induced by both dibucaine and CP as indicated by the reduction in AP frequency in response to current injection. Identifying the exact underlying mechanism, however, requires voltage-clamp work using various channel blockers. Clearly, dibucaine reduces excitability by increasing AP threshold through the blockade of AP-associated sodium channels, and CP reduces excitability by increasing the sAHP. Subtle calcium or potassium channel effects, however, cannot be excluded as both can be inhibited by local anesthetics (Hirota et al. 1997; Oda et al. 1992) . Although both drugs delayed AD through different mechanisms of reduced cortical excitability, it is unlikely that combining both drugs would delay AD any further without compromising slice health.
CA1 Neuron Recovery from OGD
The ability of single CA1 neuron to recover membrane potential after AD depends on several factors. As in our study, Tanaka et al. (1997) did not observe recovery by adult CA1 neurons in submerged slices. However, Czeh et al. (1993) demonstrated repeatable "hypoxic spreading depression" events within slices in an interface chamber. Interface slices have the advantage of a rapid diffusion rate from the oxygenrich atmosphere compared with submerged slices, which draw oxygen from the aCSF. More importantly, by lowering O 2 but not glucose, neurons still have a residual energy source and are thus not truly ischemic. We could quickly reintroduce aCSF immediately following the fast AD by observing the approaching AD front. Such neurons were able to recover full membrane potential after AD had passed the recording electrode, if the aCSF was immediately returned. Accurate recording of whole cell input resistance measured during the recovery period was difficult due to movement of the slice as it swells. However, in the cells that did not display a large increase in access resistance, whole cell input resistance levels were similar to levels measured before OGD exposure (data not shown). This indicates that an additional period of tens of seconds is required for permanent depolarization and dysfunction.
In our experiments that tested recovery of the orthodromic response in CA1 neurons, full APs could not be evoked at any time within the recovery interval (up to 40 min). EPSPs could eventually be evoked but at reduced amplitude compared with pre-OGD. In contrast, antidromic APs could be reactivated once the neuron repolarized enough to restore Na ϩ channel activation. Perhaps the lasting effects of AD cause irreparable harm to dendritic spines while preserving AP discharge. In support, no slice showed a return to LT baseline in dendritic regions in recovered slices, further indicating synaptic damage from continuing dendritic beading. Since the current space clamp is incomplete past the proximal dendrites (Brown et al. 1990) , it is possible that distal dendrites remain susceptible to OGD and continue to bead, whereas the cell body recovers to some degree. Also, whereas dendritic beading has shown recovery following brief ischemia (Murphy et al. 2008 ), CA1 population recovery following AD in slices is more problematic.
Conclusions
This study shows that at low millimolar concentrations, dibucaine (a Na ϩ channel blocker) and CP (a R ligand) maintain whole cell input resistance and membrane potential of CA1 pyramidal neurons. Therefore, the drugs do not seem to affect the baseline excitability of the neurons. However, they both reduce AP discharge, albeit in distinctly different ways, which helps explain their ability to inhibit AD onset. Reducing spike firing means lowered synaptic communication. Synaptic release/reuptake is a major expenditure of energy in the brain, yet preservation of ATP levels does not seem to be the key protective mechanism because both drugs also delay AD induced by ouabain where the ATP levels do not drop. There are likely other ways that both drug types slow AD onset, but we are still limited in our understanding of the exact mechanisms driving AD (and thus PIDs). For example, we know that the caines block the fast Na ϩ channel driving the AP, but it is not clear how effectively they bind Na ϩ channels driving the sustained and slow Na ϩ channels during OGD (APPENDIX). Indeed, it is not possible to isolate pharmacologically these channels to ascertain their contribution to the AD.
Nevertheless, our results show that the two drugs affect single pyramidal cells in distinctly different ways. It is likely that the specific pharmacophore for the caines that elicits AD inhibition and the pharmacophore for R ligands are different. Theoretically, drug design techniques can identify these pharmacophores and incorporate their properties into a single drug that might inhibit AD in the submicromolar range.
APPENDIX
Dibucaine is one of the most potent local anesthetics of the caine family based on its binding to the batrachotoxin (BTX) binding site within the pore of the voltage-gated sodium channel (Creveling et al. 1983) . IC 50 values are 1.4 M for dibucaine, 5.4 M for bupivacaine, 240 M for lidocaine, and 940 M for benzocaine (Creveling et al. 1983) . No binding occurs at the TTX binding site nor within the scorpion toxin binding site (Postma and Catterall 1984) . Initially, the uncharged caine molecule can diffuse across the nerve membrane and equilibrate with its charged form, which then binds within the Na ϩ channel near the BTX binding site on the intracellular side. During firing, caines can also enter the neuron through the open sodium channels, cumulatively binding with each depolarizing pulse (Hille 2001) . This explains the use-dependent block observed: more potent anesthetic effects arise in actively firing neurons. Use-dependent block involves a tighter binding in the inactivated state than in resting or activated states of the Na ϩ channel (Hille 2001) .
There are three types of Na ϩ channels in cortical pyramidal neurons that are likely inhibited by caines. First is the classic voltage-activated Na ϩ current driving the AP upstroke. This fast or transient Na ϩ current (I NaF ) is TTX-sensitive and rapidly activates with depolarization over a few milliseconds. Oxygen deprivation increases the probability of I NaF inactivation (O'Reilly et al. 1997), which decreases the load on the Na ϩ -K ϩ -ATPase pump to some degree, thereby lowering energy consumption.
Second is a sustained or persistent Na ϩ current (I NaP ) representing 1-4% of total Na ϩ current amplitude in normal conditions. It regulates spike threshold in a number of neuronal types, can generate Na ϩ -dependent plateau potentials, and helps drive rhythmic membrane oscillations (see Astman et al. 2006) . It is active at resting potential and resists inactivation during depolarization (Stys et al. 1993; Taylor 1993) , significantly increasing intracellular Na ϩ when activated for several seconds, as during OGD (Taylor 1993) . As such, it has been considered an O 2 sensor in central neurons (Hammarström and Gage 2000) . It is sensitive to TTX and QX-314, the former inducing a 5-to 10-mV hyperpolarization in CA1 neurons (Xie et al. 1994) . Part of the AD-delaying effect of TTX has been attributed to this increased hyperpolarization (Fung et al. 1999; Muller and Somjen 1999) .
Third, a I NaS is activated at depolarizations beyond Ϫ40 mV and reaches maximum amplitude near 0 mV. It is TTX-insensitive and activates and deactivates slowly over hundreds of milliseconds (Hoehn et al. 1993) . It is activated at levels more depolarized than Ϫ40 mV and so contributes to DAPs and the depolarizing shift driving epileptiform activity by pyramidal neurons (Hoehn et al. 1993) . The I NaS channel may also conduct K ϩ (Hoehn et al. 1993 ), which would promote K ϩ efflux during AD. I NaS is in cortical, striatal, and pyramidal neurons, so their blockade should also delay AD onset.
Dibucaine also interacts with Ca 2ϩ channels (Sugiyama and Muteki 1994) as well as affects the stability of plasma membranes (Kuroda et al. 1996) , but these effects involve higher concentrations than used in this study.
Dibucaine at 10 M elicited a significant increase in the amplitude of the CA1 fAHP in our experiments. Local anesthetics prolong the inactivated state of the sodium channel as a result of tighter binding during this state (Kuroda et al. 2000) . Prolonged inactivation could lead to increased AP duration as observed with the latter APs of a spike train compared with control CA1 neurons. What increases AP duration cannot be determined without further experiments. Aside from sodium channel alterations affecting the fAHP, the activation of voltage-gated potassium channels and Ca 2ϩ -activated K ϩ currents could also increase the fAHP as reported in pyramidal neurons (Bekkers 2000; Sah 1996) . However, the caines have not been shown to affect these currents (Creveling et al. 1983) .
CP is a R ligand. It is a 26-kDa protein with two known subtypes (1 and 2) in a single membrane-spanning domain (Gundlach et al. 1986 ). Its function is unknown. The 1R is widely located within the rat CNS, particularly neuronal cell bodies and dendrites of brain stem, hypothalamus, and hippocampus, but not axon fibers or terminals (Hanner et al. 1996) . Intracellular location includes both the plasma membrane and intracellular compartments such as mitochondrial membrane and ER (Alonso et al. 2000) . Activation of 1R increases delayed outwardly rectifying K ϩ currents (Wilke et al. 1999) , BK channels, and the M-current within cardiac neurons (Zhang and Cuevas 2005) .
